Lapatinib
- Generic Name
- Lapatinib
- Brand Names
- Tykerb, Tyverb
- Drug Type
- Small Molecule
- Chemical Formula
- C29H26ClFN4O4S
- CAS Number
- 231277-92-2
- Unique Ingredient Identifier
- 0VUA21238F
- Background
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2...
- Indication
Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.
- Associated Conditions
- Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
- Conditions
- Interventions
- Drug: Oncology DrugsDrug: ErlotinibDrug: TrastuzumabDrug: Trastuzumab emtansineDrug: PertuzumabDrug: LapatinibDrug: EverolimusDrug: VemurafenibDrug: CobimetinibDrug: AlectinibDrug: BrigatinibDrug: PalbociclibDrug: PonatinibDrug: VismogedibDrug: ItacitinibDrug: IpatasertibDrug: EntrectinibDrug: AtezolizumabDrug: NivolumabDrug: IpilimumabDrug: PemigatinibDrug: PralsetinibDrug: SelpercatinibDrug: TalazoparibDrug: TepotinibDrug: Alpelisib
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Fondazione per la Medicina Personalizzata
- Target Recruit Count
- 400
- Registration Number
- NCT04591431
- Locations
- 🇮🇹
I.R.S.T. Srl Irccs, Meldola, Italy
🇮🇹Ospedale Classificato Sacro Cuore - Don Calabria, Negrar, Italy
🇮🇹I.R.C.C.S. Istituto Oncologico Veneto, Padova, Italy
The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2019-12-04
- Lead Sponsor
- Bio-Thera Solutions
- Target Recruit Count
- 410
- Registration Number
- NCT04185649
- Locations
- 🇨🇳
Beijing Shijitan Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
Molecular Profiling of Advanced Soft-tissue Sarcomas
- Conditions
- Interventions
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2024-04-10
- Target Recruit Count
- 603
- Registration Number
- NCT03784014
- Locations
- 🇫🇷
Centre Oscar Lambret, Lille, France
🇫🇷IUCT Oncopôle, Toulouse, France
🇫🇷Institut de Cancérologie de Montpellier, Montpellier, France
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
- Conditions
- Interventions
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 608
- Registration Number
- NCT03523585
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸The Methodist Hospital Research Institute, Houston, Texas, United States
🇧🇪Az Groeninge, Kortrijk, Belgium
A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 301
- Registration Number
- NCT03500380
- Locations
- 🇨🇳
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
🇨🇳Peking University People's Hospital, Beijing, China
🇨🇳The First Affiliated Hospital of Bengbu Medical College, Bengbu, China
Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-09-06
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03273595
- Locations
- 🇨🇳
Xijing Hospital, Xi'an, Shanxi, China
Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 351
- Registration Number
- NCT03084939
- Locations
- 🇨🇳
Beijing Hospital, Beijing City, China
🇨🇳Beijing Cancer Hospital, Beijing, China
🇨🇳Changzhou First People's Hospital, Changzhou, China
Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
- First Posted Date
- 2016-07-19
- Last Posted Date
- 2018-05-07
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 152
- Registration Number
- NCT02836847
- Locations
- 🇨🇳
Xinhua Hospital, Shanghai, Shanghai, China
Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2016-04-28
- Lead Sponsor
- Akros Pharma Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02581124
A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab
- Conditions
- Interventions
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2018-07-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 128
- Registration Number
- NCT02422199
- Locations
- 🇨🇳
307 Hospital Affiliated to Academy Military Medical Science, Beijing, China
🇨🇳Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.